These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38092225)

  • 1. Dupilumab Improves Lung Function Parameters in Pediatric Type 2 Asthma: VOYAGE Study.
    Bacharier LB; Guilbert TW; Katelaris CH; Deschildre A; Phipatanakul W; Liu D; Altincatal A; Mannent LP; Amin N; Laws E; Akinlade B; Jacob-Nara JA; Deniz Y; Rowe PJ; Lederer DJ; Hardin M
    J Allergy Clin Immunol Pract; 2024 Apr; 12(4):948-959. PubMed ID: 38092225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma.
    Bacharier LB; Maspero JF; Katelaris CH; Fiocchi AG; Gagnon R; de Mir I; Jain N; Sher LD; Mao X; Liu D; Zhang Y; Khan AH; Kapoor U; Khokhar FA; Rowe PJ; Deniz Y; Ruddy M; Laws E; Patel N; Weinreich DM; Yancopoulos GD; Amin N; Mannent LP; Lederer DJ; Hardin M;
    N Engl J Med; 2021 Dec; 385(24):2230-2240. PubMed ID: 34879449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma.
    Bacharier LB; Pavord ID; Maspero JF; Jackson DJ; Fiocchi AG; Mao X; Jacob-Nara JA; Deniz Y; Laws E; Mannent LP; Amin N; Akinlade B; Staudinger HW; Lederer DJ; Hardin M
    J Allergy Clin Immunol; 2024 Jul; 154(1):101-110. PubMed ID: 38272375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Lung Function on Asthma Exacerbation Rates in Children Treated with Dupilumab: The VOYAGE Study.
    Guilbert TW; Murphy KR; Hamelmann E; Ross KR; Gupta A; Fiocchi A; Xia C; Gall R; Ledanois O; Radwan A; Jacob-Nara JA; Rowe PJ; Deniz Y
    J Asthma Allergy; 2024; 17():81-87. PubMed ID: 38347908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Exacerbation History on Dupilumab Efficacy in Children with Uncontrolled Moderate-to-Severe Asthma: LIBERTY ASTHMA VOYAGE Study.
    Guilbert TW; Tolcachier A; Fiocchi AG; Katelaris CH; Phipatanakul W; Begin P; de Mir I; Altincatal A; Gall R; Ledanois O; Radwan A; Jacob-Nara JA; Deniz Y; Rowe PJ
    J Asthma Allergy; 2024; 17():143-159. PubMed ID: 38476213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dupilumab is effective in type 2-high asthma patients receiving high-dose inhaled corticosteroids at baseline.
    Bourdin A; Papi AA; Corren J; Virchow JC; Rice MS; Deniz Y; Djandji M; Rowe P; Pavord ID
    Allergy; 2021 Jan; 76(1):269-280. PubMed ID: 33010038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dupilumab efficacy in subgroups of type 2 asthma with high-dose inhaled corticosteroids at baseline.
    Bourdin A; Virchow JC; Papi A; Lugogo NL; Bardin P; Antila M; Halpin DMG; Daizadeh N; Djandji M; Ortiz B; Jacob-Nara JA; Gall R; Deniz Y; Rowe PJ
    Respir Med; 2022 Oct; 202():106938. PubMed ID: 36087550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
    Wenzel S; Castro M; Corren J; Maspero J; Wang L; Zhang B; Pirozzi G; Sutherland ER; Evans RR; Joish VN; Eckert L; Graham NM; Stahl N; Yancopoulos GD; Louis-Tisserand M; Teper A
    Lancet; 2016 Jul; 388(10039):31-44. PubMed ID: 27130691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-to-Severe Asthma.
    Pavord ID; Deniz Y; Corren J; Casale TB; FitzGerald JM; Izuhara K; Daizadeh N; Ortiz B; Johnson RR; Harel S; Djandji M; Goga L; Crikelair N; Rowe PJ; Busse WW
    J Allergy Clin Immunol Pract; 2023 Apr; 11(4):1213-1220.e2. PubMed ID: 36535524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction.
    Hanania NA; Castro M; Bateman E; Pavord ID; Papi A; FitzGerald JM; Maspero JF; Katelaris CH; Singh D; Daizadeh N; Altincatal A; Pandit-Abid N; Soler X; Siddiqui S; Laws E; Jacob-Nara JA; Rowe PJ; Lederer DJ; Hardin M; Deniz Y
    Ann Allergy Asthma Immunol; 2023 Feb; 130(2):206-214.e2. PubMed ID: 36332763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dupilumab sustains lung function improvements in patients with moderate-to-severe asthma.
    Papi A; Castro M; Corren J; Pavord ID; Tohda Y; Altincatal A; Pandit-Abid N; Laws E; Akinlade B; Mannent LP; Gall R; Jacob-Nara JA; Deniz Y; Rowe PJ; Lederer DJ; Hardin M
    Respir Med; 2024 Apr; 224():107535. PubMed ID: 38272376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dupilumab efficacy and safety in Japanese patients with uncontrolled, moderate-to-severe asthma in the phase 3 LIBERTY ASTHMA QUEST study.
    Tohda Y; Nakamura Y; Fujisawa T; Ebisawa M; Arima K; Miyata M; Takahashi Y; Rice MS; Deniz Y; Rowe P; Patel N; Graham NMH; Teper A
    Allergol Int; 2020 Oct; 69(4):578-587. PubMed ID: 32444306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dupilumab sustains efficacy in patients with moderate-to-severe type 2 asthma regardless of inhaled corticosteroids dose.
    Pavord ID; Bourdin A; Papi A; Domingo C; Corren J; Altincatal A; Radwan A; Pandit-Abid N; Jacob-Nara JA; Deniz Y; Rowe PJ; Laws E; Lederer DJ; Hardin M
    Allergy; 2023 Nov; 78(11):2921-2932. PubMed ID: 37431558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dupilumab 200 mg was efficacious in children (6-11 years) with moderate-to-severe asthma for up to 2 years: EXCURSION open-label extension study.
    Phipatanakul W; Vogelberg C; Bacharier LB; Dell S; Altincatal A; Gall R; Ledanois O; Sacks H; Jacob-Nara JA; Deniz Y; Rowe PJ
    Pediatr Pulmonol; 2024 Jul; ():. PubMed ID: 39016623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dupilumab Is Effective in Patients With Moderate-to-Severe Uncontrolled GINA-Defined Type 2 Asthma Irrespective of an Allergic Asthma Phenotype.
    Rabe KF; FitzGerald JM; Bateman ED; Castro M; Pavord ID; Maspero JF; Busse WW; Izuhara K; Daizadeh N; Ortiz B; Pandit-Abid N; Rowe PJ; Deniz Y
    J Allergy Clin Immunol Pract; 2022 Nov; 10(11):2916-2924.e4. PubMed ID: 36028446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma.
    Castro M; Rabe KF; Corren J; Pavord ID; Katelaris CH; Tohda Y; Zhang B; Rice MS; Maroni J; Rowe P; Pirozzi G; Amin N; Ruddy M; Akinlade B; Graham NMH; Teper A
    ERJ Open Res; 2020 Jan; 6(1):. PubMed ID: 32010719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dupilumab leads to better-controlled asthma and quality of life in children: the VOYAGE study.
    Fiocchi AG; Phipatanakul W; Zeiger RS; Durrani SR; Cole J; Msihid J; Gall R; Jacob-Nara JA; Deniz Y; Rowe PJ; Lederer DJ; Hardin M; Zhang Y; Khan AH
    Eur Respir J; 2023 Nov; 62(5):. PubMed ID: 37734856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dupilumab Reduces Exacerbations Independent of Changes in Biomarkers in Moderate-to-Severe Asthma.
    Pavord ID; Casale TB; Corren J; FitzGerald MJ; Deniz Y; Altincatal A; Gall R; Pandit-Abid N; Radwan A; Jacob-Nara JA; Rowe PJ; Busse WW
    J Allergy Clin Immunol Pract; 2024 Jul; 12(7):1763-1772. PubMed ID: 38555079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic Rhinosinusitis.
    Maspero JF; Katelaris CH; Busse WW; Castro M; Corren J; Chipps BE; Peters AT; Pavord ID; Ford LB; Sher L; Rabe KF; Rice MS; Rowe P; Lu Y; Harel S; Jagerschmidt A; Khan AH; Kamat S; Pirozzi G; Amin N; Ruddy M; Graham NMH; Mannent LP; Teper A
    J Allergy Clin Immunol Pract; 2020 Feb; 8(2):527-539.e9. PubMed ID: 31351189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of dupilumab in children with moderate-to-severe type 2 asthma with or without evidence of allergic asthma.
    Papadopoulos NG; Szefler SJ; Bacharier LB; Maspero JF; Domingo C; Fiocchi A; Lee JK; Daizadeh N; Lederer DJ; Hardin M; Gall R; Djandji M; Siddiqui S; Jacob-Nara JA; Deniz Y; Rowe PJ
    Allergy; 2023 Aug; 78(8):2157-2167. PubMed ID: 37059696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.